Blog

Emma M. Groarke: We found that there was more than 40% cumulative incidence of venous and arterial thrombosis in patients with VEXAS

Photo from Emma M. Groarke/X

Feb 8, 2024, 14:58

Emma M. Groarke: We found that there was more than 40% cumulative incidence of venous and arterial thrombosis in patients with VEXAS

Emma M. Groarke, Hematologist at the National Institutes of Health (NIH), shared a post on X/Twitter:

“Very excited to share our NIH-Mayo Clinic collaboration just published in Blood Journal focused on the thrombotic manifestations occurring in VEXAS.

We found that there was >40% cumulative incidence of venous and arterial thrombosis in patients with VEXAS; many events occurred at initial disease presentation. Cardiac or pulmonary involvement appear to confer increased risk.

Thrombosis seems to be driven by inflammation. Patients almost ubiquitously had high FVIII levels and many had high VWD antigen and activity.”

Source: Emma M. Groarke/X

Blood Journal cancer Emma M. Groarke Mayo Clinic National Institutes of Health (NIH). NIH OncoDaily Oncology venous and arterial thrombosis Vexas VWD antigen

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage